Patients experiencing symptoms such as chest pain who received from paramedics an intravenous solution consisting of glucose-insulin-potassium (GIK) had no reduction in the rate of progression to heart attack and no improvement ...
Mar 27, 2012
0
0
Human geneticists have long debated whether the genetic risk of the most common medical conditions derive from many rare mutations, each conferring a high degree of risk in different people, or common differences throughout ...
Mar 25, 2012
0
0
Cellular reversion processes arise in diseases of the heart muscle, for example myocardial infarction and cardiomyopathy, which limit the fatal consequences for the organ. Scientists from the Max Planck Institute for Heart ...
Nov 11, 2011
0
0
(Medical Xpress) -- Researchers at Columbia Engineering have established a new method to patch a damaged heart using a tissue-engineering platform that enables heart tissue to repair itself. This breakthrough, recently published ...
May 6, 2011
0
0
A new guideline from the American College of Physicians (ACP) offers clinical recommendations for the use of newer pharmacological treatments of adults with type 2 diabetes. This is an update of ACP's 2017 guideline and is ...
Apr 19, 2024
0
4
Referring people to a specialized rehabilitation program following a cardiac incident could reduce the chance they will be readmitted to hospital and potentially lower their risk of death, according to new Flinders University ...
Apr 11, 2024
0
0
For patients with acute myocardial infarction at risk for heart failure, empagliflozin reduces the risk for heart failure hospitalization, according to a study published online April 6 in Circulation to coincide with the ...
Apr 8, 2024
0
0
While the composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack
Apr 8, 2024
0
0
About 800,000 people in the U.S. suffer a heart attack every year, and about 30% of them will go on to develop heart failure. There are limited treatments to prevent or slow that development.
Apr 8, 2024
0
0
A new meta-analysis shows sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of major adverse cardiovascular events in patients with either diabetes at high risk of atherosclerotic cardiovascular disease (ASCVD), ...
Apr 8, 2024
0
0
